The FOSRENOL^® Focus

Perspective From Renal Dietitians

The FOSRENOL^® Focus is an interactive program featuring several renal dietitians discussing different aspects of treating CKD Stage 5 and how FOSRENOL^® may benefit your patients.

The questions reviewed in the FOSRENOL^® Focus include:

How does FOSRENOL^® help reduce your patients' pill burden?
What can I do to encourage changes in my patients' diet?
How can I help my patients get involved in managing their hyperphosphatemia?
How can phosphate binders benefit patients?
What is the long-term safety profile of FOSRENOL^®?

Low Bandwidth
(56K Dialup)

Click Here to launch FOSRENOL^®Focus, optimized for 56K dialup internet connection
High Bandwidth
(Broadband)

Click Hereto launch FOSRENOL^®Focus, optimized for a broadband internet connection

To view this program, you need a free plug-in called Macromedia Flash Player installed on your computer. To download and install Flash, click the button.

If you have difficulty viewing the online program, you can download a transcript of the program.

FOSRENOL^® is indicated to reduce serum phosphate in patients with end-stage renal disease.

* Maintenance of reduction was observed for up to 3 years in patients treated with FOSRENOL^®.

Send to a Colleague

Important Safety Information

The most common adverse events were gastrointestinal, such as nausea and vomiting, and generally abated over time with continued dosing
The most common side effects leading to discontinuation in clinical trials were gastrointestinal events (nausea, vomiting, and diarrhea)
Other side effects reported in trials included dialysis graft complications, headache, abdominal pain, and hypotension
Although studies were not designed to detect differences in risk of fracture and mortality, there were no differences demonstrated in patients treated with FOSRENOL^® compared to alternative therapy for up to 3 years
The duration of treatment exposure and time of observation in the clinical program were too short to conclude that FOSRENOL^® does not affect the risk of fracture or mortality beyond 3 years
While lanthanum has been shown to accumulate in the GI tract, liver, and bone in animals, the clinical significance in humans is unknown
Patients with acute peptic ulcer, ulcerative colitis, Crohn's disease, or bowel obstruction were not included in FOSRENOL^® clinical studies. Caution should be used in patients with these conditions
FOSRENOL^® should not be taken by patients who are nursing or pregnant
FOSRENOL^® should not be taken by patients who are under 18 years of age

This site is strictly intended for US residents and is governed solely by US laws and governmental regulations. Please see our online privacy policy for more information.

While Shire US Inc. makes reasonable efforts to include accurate, up-to-date information on the site, Shire US Inc. makes no warranties or representations as to its accuracy. Shire US Inc. assumes no liability for any errors or omissions in the content of the site.

FOS1726 1/15/2008

The FOSRENOL^® Focus

Perspective From Renal Dietitians

Low Bandwidth
(56K Dialup)

High Bandwidth
(Broadband)

Important Safety Information

The FOSRENOL® Focus

Perspective From Renal Dietitians

Low Bandwidth (56K Dialup)

High Bandwidth (Broadband)

Important Safety Information

The FOSRENOL^® Focus

Low Bandwidth
(56K Dialup)

High Bandwidth
(Broadband)